What is the 13F Pro Quality Score for MRKR?

13F Pro ranks Marker Therapeutics, Inc. (MRKR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MRKR's current score at https://13fpro.ai/research/MRKR (free sign-up required for the full ranking).

Where does 13F Pro source MRKR data?

All Marker Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Marker Therapeutics, Inc. files with the SEC under CIK 1094038. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MRKR in?

Marker Therapeutics, Inc. (MRKR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MRKR research updated on 13F Pro?

MRKR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Marker Therapeutics, Inc.(MRKR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1094038 MRKR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $6.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MRKR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Marker Therapeutics, Inc. (MRKR), a Healthcare sector company. MRKR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $6.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Marker Therapeutics, Inc. reports quarterly revenue of $751.7K, net income of $-3.2M, free cash flow of $-1.4M. Top institutional holders of MRKR by reported 13-F value include NEA Management Company,, Blue Owl Capital Holdings, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MRKR trades on the Nasdaq exchange and files with the SEC under CIK 1094038. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRKR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Marker Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$751.7K

Net Income

Q1 2026

$-3.2M

Free Cash Flow

Q1 2026

$-1.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-46.2% YoY

$3.5MFY 2025

FY22 $3.5MFY23 $3.3MFY24 $6.6MFY25 $3.5M

Net Income

-13.3% YoY

$-12.2MFY 2025

FY22 $-29.9MFY23 $-8.2MFY24 $-10.7MFY25 $-12.2M

Operating Income

-15.9% YoY

$-12.9MFY 2025

FY22 $-19.8MFY23 $-14.6MFY24 $-11.1MFY25 $-12.9M

EPS (Diluted)

+33.6% YoY

$-0.79FY 2025

FY22 $-3.58FY23 $-0.94FY24 $-1.19FY25 $-0.79

Total Assets

-13.4% YoY

$19.1MFY 2025

FY22 $34.4MFY23 $17.1MFY24 $22.0MFY25 $19.1M

Op. Cash Flow

-10.1% YoY

$-12.0MFY 2025

FY22 $-27.0MFY23 $-16.4MFY24 $-10.9MFY25 $-12.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2017	FY 2015
Revenue	$3.5M -46.2%	$6.6M +99.1%	$3.3M -5.8%	$3.5M +1819.3%	$183.1K	—
Net Income	$-12.2M -13.3%	$-10.7M -30.3%	$-8.2M +72.5%	$-29.9M -172.5%	$-11.0M +67.8%	$-34.1M
Operating Income	$-12.9M -15.9%	$-11.1M +23.7%	$-14.6M +26.3%	$-19.8M -72.4%	$-11.5M -86.4%	$-6.2M
EPS (Diluted)	$-0.79 +33.6%	$-1.19 -26.6%	$-0.94 +73.7%	$-3.58 -208.6%	$-1.16 +85.0%	$-7.76
Total Assets	$19.1M -13.4%	$22.0M +28.6%	$17.1M -50.2%	$34.4M +564.5%	$5.2M -22.0%	$6.6M
Operating Cash Flow	$-12.0M -10.1%	$-10.9M +33.6%	$-16.4M +39.0%	$-27.0M -219.6%	$-8.4M -94.3%	$-4.3M

AI Insight: MRKR Financial Trends

Marker remains pre-revenue with modest operational losses, but operating cash burn has stabilized near $1–2M quarterly.

• Operating cash flow improved from −$5M in Q1 2025 to −$1M in Q1 2026, showing material reduction in cash consumption.

• Revenue flat at $1M for four consecutive quarters (Q2 2025–Q1 2026), indicating no commercial traction yet.

• Net losses stabilized at $2–3M quarterly since Q3 2025, down from $4M peaks in late 2024–mid-2025.

⚠ Equity volatility: swung from $10M (Q2 2025) to $18M (Q3 2025), suggesting capital raises or write-downs. Monitor dilution.

⚠ Revenue remains negligible ($0–2M across 8 quarters); no evidence of pipeline advancement or commercial inflection.

AI Insight: MRKR Ratio Trends

Marker Therapeutics remains deeply unprofitable across all profitability metrics, with operating margins around -170% and ROIC near -45%, showing no clear path to breakeven.

• Operating margin stabilized around -170% in Q4 2025 and TTM, after volatility between -125% and -197% in 2024.

• ROE improved significantly from -153.1% in Q2 2025 to -40.6% in Q4 2025, suggesting reduced losses relative to equity base.

• ROIC hovered near -45% to -47% in Q3–Q4 2025, substantially better than -83% to -95% levels in mid-2024.

⚠ ROE deteriorated sharply to -92.2% in Q1 2026 from -40.6% in Q4 2025, reversing recent improvement trend.

⚠ All profitability metrics remain deeply negative; company has not yet demonstrated sustainable positive cash generation.

Get alerted when MRKR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Marker Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MRKR

NEA Management Company, LLC
$2.1M1,625,678 sh
Blue Owl Capital Holdings LP
$720.5K554,250 sh
VANGUARD CAPITAL MANAGEMENT LLC
$506.1K389,319 sh
Aisling Capital Management LP
$423.0K325,370 sh
RENAISSANCE TECHNOLOGIES LLC
$227.9K175,294 sh
GEODE CAPITAL MANAGEMENT, LLC
$209.2K160,910 sh
OSAIC HOLDINGS, INC.
$121.1K93,121 sh
VANGUARD FIDUCIARY TRUST CO
$113.5K87,269 sh
LPL Financial LLC
$108.0K83,047 sh
XTX Topco Ltd
$82.6K63,567 sh

Fund	Value	Shares
NEA Management Company, LLC	$2.1M	1,625,678
Blue Owl Capital Holdings LP	$720.5K	554,250
VANGUARD CAPITAL MANAGEMENT LLC	$506.1K	389,319
Aisling Capital Management LP	$423.0K	325,370
RENAISSANCE TECHNOLOGIES LLC	$227.9K	175,294
GEODE CAPITAL MANAGEMENT, LLC	$209.2K	160,910
OSAIC HOLDINGS, INC.	$121.1K	93,121
VANGUARD FIDUCIARY TRUST CO	$113.5K	87,269
LPL Financial LLC	$108.0K	83,047
XTX Topco Ltd	$82.6K	63,567

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MRKR on your watchlist

Track score changes the day Marker Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MRKR a good stock to buy?

13F Pro's AI-powered analysis of Marker Therapeutics, Inc. (MRKR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MRKR are available on the MRKR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MRKR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MRKR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Marker Therapeutics, Inc.'s investment landscape.